Johnson & Johnson begins development of a vaccine against the omicron strain

American company Johnson & amp; Johnson will develop a vaccine against the omicron-strain of coronavirus

American company Johnson & Johnson has begun development of a vaccine against the omicron-strain of coronavirus. TASS writes about this with reference to the company's statement.

It is noted that the company, in collaboration with scientists from South Africa and around the world, is evaluating the effectiveness of its COVID-19 vaccine against various options, including “a new, rapidly spreading omicron strain. ” an authority in the United States wanted to announce that the use of the coronavirus vaccine by the American company Johnson & Johnson could increase the risk of developing a rare autoimmune disease. It was clarified that patients who received this drug in the United States are about three to five times more likely to develop Guillain-Barré syndrome, an autoimmune lesion of peripheral nerves, accompanied by muscle weakness and sensory impairment.

< p>